非癌症手术患者围术期缓释阿片类药物处方实践:2015-2018年
这项回顾性队列研究基于加州大学旧金山医学中心电子健康记录,纳入25396例2015-2018年全身麻醉下择期手术的成人非癌症患者,评估围术期缓释阿片类药物处方实践。研究发现术前使用缓释阿片类药物者术后阿片类药物用量约为未使用者的两倍,且术前缓释阿片使用者中五分之一在住院期间被逐渐减停而未影响疼痛或住院时间。
要点
- 术前使用缓释阿片类药物者术后阿片用量约为未使用者的两倍
- 术前缓释阿片使用者中五分之一住院期间被减停且未影响疼痛或住院时间
- 术前缓释阿片使用者中五分之四术后继续使用缓释阿片
核心结论
- 住院非癌症手术患者的围术期缓释阿片处方实践因术前阿片使用情况和手术类型而存在显著差异。
- 疼痛医学从业者和外科医生可能在应对手术相关缓释阿片暴露风险和减少阿片相关并发症方面发挥重要作用。
研究设计与样本
- 回顾性队列研究,使用加州大学旧金山医学中心电子健康记录数据。
- 纳入25396例2015-2018年全身麻醉下择期手术的成人非癌症患者。
主要发现
- 物质使用障碍诊断、阿片使用、手术类型和术后非阿片镇痛药使用与术后阿片给药相关(P < .0001)。
- 术前缓释阿片使用者术后口服吗啡当量估计调整均值(95%CI)为170.08 mg(147.08-196.67),未使用阿片者為81.36 mg(70.7-93.63),P < .0001。
- 术前缓释阿片使用者中五分之一在住院期间被减停缓释阿片,未对术后疼痛或住院时间造成不良影响。
- 术前缓释阿片使用者中五分之四术后也接受了缓释阿片,而未使用阿片者中百分之一住院期间接受了缓释阿片。
临床怎么用
- 对于术前使用缓释阿片的非癌症手术患者,可考虑在住院期间逐渐减停缓释阿片,而不影响术后疼痛或住院时间。
- 应关注术前阿片使用情况和手术类型对围术期缓释阿片处方实践的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extended-release (ER) opioids are indicated for the management of persistent moderate to severe pain in patients requiring around-the-clock opioid analgesics for an extended period of time. Concerns have been raised regarding safety of ER opioids due to its potential for abuse and dependence. However, little is known about perioperative prescribing practices of ER opioids. This study assessed perioperative prescribing practices of ER opioids in noncancer surgical patients stratified by type of opioid exposure prior to admission and examined predictors of postoperative opioid administration in oral morphine equivalents (OME). METHODS: This was a retrospective cohort study using the University of California San Francisco Medical Center electronic health record data. This study included 25,396 adult noncancer patients undergoing elective surgery under general anesthesia in the period 2015-2018. The primary study outcome was predictors of postoperative administration of opioids in hospitalized surgical patients. Secondary outcomes included patients discontinued and initiated on ER opioids during their hospital stay. RESULTS: substance use disorder diagnosis and use of opioids, surgery type, and postoperative administration of nonopioid analgesics were associated with postoperative administration of opioids (P < .0001). The estimated adjusted mean (95% confidence interval [CI]) of postoperative administration of OME prior to admission in ER opioid users (170.08 mg; 147.08-196.67) was twice the amount for opioid-naïve patients (81.36 mg; 70.7-93.63; P < .0001). One in 5 prior to admission ER opioid users were weaned off ER opioids while hospitalized without adversely affecting their postoperative pain or hospital length of stay (LOS). Four of 5 patients who used ER opioids prior to admission also received ER opioids after surgery, whereas, 1 in 100 opioid-naïve patients received ER opioids during their hospital stay. CONCLUSIONS: We found significant variability in the perioperative prescribing practices of ER opioids in hospitalized noncancer surgical patients by use of opioids prior to admission and surgery type. Pain medicine practitioners and surgeons may play a significant role tackling the surgery-related risk of exposure to ER opioids and decreasing opioid-related complications.
引用
- Rodriguez-Monguio R, Naveed M, Croci R, et al. Perioperative Prescribing Practices of Extended-Release Opioids in Noncancer Surgical Patients, 2015-2018. Anesth Analg. 2020. PMID: 32925346. doi:10.1213/ANE.0000000000004952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。